Immunitybio Inc
NASDAQ:IBRX

Watchlist Manager
Immunitybio Inc Logo
Immunitybio Inc
NASDAQ:IBRX
Watchlist
Price: 6.52 USD -2.4%
Updated: May 27, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Cash Flow Statement

-389.4m
-6%
Operating Cash Flow
Growth Rates:
1 Year
-12%
3 Years
-94%
5 Years
-539%
7 Years
-879%
10 Years
-
-57.6m
-89%
Investing Cash Flow
Growth Rates:
1 Year
-
3 Years
-2 854%
5 Years
-
7 Years
-
10 Years
-
491.7m
-12%
Financing Cash Flow
Growth Rates:
1 Year
+58%
3 Years
+160%
5 Years
+1 176%
7 Years
-
10 Years
-

Cash Flow Statement
Immunitybio Inc

Rotate your device to view
Cash Flow Statement
Currency: USD
Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024
Operating Cash Flow
Net Income
(6)
(38)
(167)
(213)
(237)
(235)
(138)
(123)
(121)
(115)
(104)
(96)
(96)
(99)
(104)
(103)
(96)
(87)
(76)
(67)
(160)
(180)
(215)
(266)
(224)
(267)
(305)
(327)
(350)
(372)
(378)
(401)
(417)
(431)
(474)
(459)
(584)
(601)
Depreciation & Amortization
0
0
1
1
1
2
1
2
4
4
5
6
6
6
7
8
10
10
10
10
14
15
16
18
13
12
13
13
14
15
16
17
18
19
19
19
19
18
Change in Deffered Taxes
0
0
0
0
(0)
(0)
(1)
(1)
(1)
(1)
(0)
(0)
(1)
(1)
(1)
(1)
(1)
(0)
(0)
(0)
(0)
(1)
(1)
(3)
(3)
(2)
(2)
(0)
(0)
0
0
0
0
0
0
0
0
0
Stock-Based Compensation
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
2
17
35
49
57
52
44
41
40
41
42
46
49
47
Other Non-Cash Items
2
26
153
192
210
205
102
83
75
66
52
42
39
38
37
32
24
17
10
7
10
12
12
25
26
34
54
63
80
83
83
74
70
55
78
74
195
221
Cash Taxes Paid
0
0
0
0
0
0
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash Interest Paid
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
1
1
2
7
12
22
35
46
50
47
77
86
Change in Working Capital
(1)
(1)
0
3
0
1
2
0
4
6
1
3
3
2
5
1
(1)
(1)
(6)
(9)
(16)
(16)
(11)
6
16
22
16
(9)
(19)
(15)
(31)
(8)
(8)
10
41
23
4
(28)
Cash from Operating Activities
(5)
N/A
(13)
-134%
(13)
-6%
(17)
-26%
(25)
-49%
(27)
-6%
(32)
-21%
(39)
-20%
(39)
+1%
(40)
-3%
(46)
-17%
(46)
+1%
(49)
-6%
(54)
-11%
(56)
-2%
(63)
-13%
(63)
-1%
(61)
+4%
(62)
-1%
(61)
+2%
(152)
-151%
(170)
-12%
(199)
-17%
(220)
-10%
(172)
+22%
(201)
-17%
(225)
-12%
(260)
-16%
(274)
-5%
(289)
-5%
(311)
-7%
(318)
-3%
(338)
-6%
(347)
-3%
(335)
+3%
(342)
-2%
(367)
-7%
(389)
-6%
Investing Cash Flow
Capital Expenditures
(0)
(0)
(1)
(1)
(2)
(3)
(4)
(6)
(7)
(10)
(17)
(25)
(35)
(35)
(30)
(23)
(13)
(10)
(9)
(6)
(4)
(3)
(2)
(3)
(2)
(8)
(16)
(22)
(34)
(75)
(83)
(91)
(99)
(59)
(52)
(42)
(31)
(23)
Other Items
0
(2)
(2)
(2)
(173)
(272)
(281)
(271)
(107)
14
88
96
134
122
81
83
70
45
34
31
23
55
57
(15)
(18)
6
10
83
(51)
(111)
3
(1)
127
147
15
(10)
0
(34)
Cash from Investing Activities
(0)
N/A
(2)
-775%
(3)
-27%
(3)
-16%
(175)
-5 571%
(275)
-57%
(285)
-3%
(277)
+3%
(114)
+59%
4
N/A
71
+1 565%
71
+0%
100
+40%
86
-13%
51
-41%
61
+19%
57
-6%
35
-39%
25
-29%
25
+2%
19
-26%
52
+180%
56
+8%
(18)
N/A
(20)
-9%
(2)
+90%
(7)
-246%
60
N/A
(85)
N/A
(186)
-119%
(80)
+57%
(92)
-15%
27
N/A
88
+223%
(37)
N/A
(52)
-39%
(30)
+41%
(58)
-89%
Financing Cash Flow
Net Issuance of Common Stock
1
1
4
2
1
(1)
(11)
(11)
(16)
(14)
(19)
(16)
(15)
(15)
(3)
(3)
(0)
39
38
38
67
27
115
115
87
86
97
139
166
167
69
27
60
107
121
159
107
70
Net Issuance of Debt
63
63
128
373
316
316
245
0
(0)
(0)
(5)
(20)
(20)
(20)
(15)
(0)
(0)
(0)
(0)
(0)
48
48
0
111
64
104
104
40
339
299
299
423
174
204
234
308
451
422
Other
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
(0)
(0)
(0)
(0)
(0)
0
0
Cash from Financing Activities
64
N/A
65
+0%
133
+105%
376
+183%
317
-16%
315
-1%
235
-26%
(11)
N/A
(16)
-39%
(14)
+9%
(24)
-70%
(36)
-50%
(35)
+3%
(35)
+1%
(18)
+47%
(4)
+81%
(1)
+78%
39
N/A
38
-1%
38
+0%
114
+199%
75
-34%
163
+117%
226
+39%
151
-33%
189
+26%
200
+6%
180
-10%
505
+181%
467
-8%
368
-21%
450
+22%
234
-48%
311
+33%
354
+14%
468
+32%
558
+19%
492
-12%
Change in Cash
Effect of Foreign Exchange Rates
0
0
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(0)
0
(0)
(0)
(0)
(0)
(0)
0
0
(0)
0
0
0
0
(0)
(0)
(0)
(0)
Net Change in Cash
59
N/A
50
-15%
116
+134%
355
+205%
117
-67%
13
-89%
(82)
N/A
(327)
-298%
(168)
+49%
(50)
+70%
1
N/A
(10)
N/A
16
N/A
(2)
N/A
(23)
-855%
(6)
+76%
(7)
-26%
12
N/A
1
-89%
3
+111%
(19)
N/A
(43)
-123%
19
N/A
(12)
N/A
(41)
-244%
(14)
+66%
(31)
-124%
(20)
+35%
146
N/A
(8)
N/A
(22)
-164%
40
N/A
(76)
N/A
52
N/A
(18)
N/A
74
N/A
161
+118%
45
-72%
Free Cash Flow
Free Cash Flow
(6)
N/A
(13)
-129%
(14)
-11%
(18)
-27%
(28)
-51%
(30)
-9%
(36)
-20%
(45)
-25%
(45)
0%
(50)
-10%
(64)
-28%
(71)
-11%
(84)
-18%
(89)
-7%
(85)
+5%
(85)
0%
(76)
+11%
(71)
+7%
(70)
+1%
(66)
+6%
(156)
-137%
(173)
-10%
(201)
-16%
(223)
-11%
(173)
+22%
(210)
-21%
(241)
-15%
(283)
-17%
(308)
-9%
(364)
-18%
(394)
-8%
(409)
-4%
(437)
-7%
(406)
+7%
(387)
+5%
(384)
+1%
(397)
-4%
(413)
-4%

See Also

Summary
IBRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
IBRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IBRX stock valuation using valuation multiples.
Wall Street Estimates
IBRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IBRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 141,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.